Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-23 | New | Yet to Sell | $0 | Equity Only | 06c | SEC link |
| 2024-06-24 | Amended | $170,000 | $0 | Debt Only | 06b | SEC link |
| 2024-05-28 | New | $130,000,000 | $170,000 | Debt Only | 06b | SEC link |
| 2023-02-17 | New | $7,999,996 | $7,999,996 | Equity Only | 06b | SEC link |
| 2022-08-08 | New | $2,598,156 | $2,598,156 | Debt Only | 06b | SEC link |
| 2021-02-03 | New | $280,000 | $280,000 | Debt Only | 06b | SEC link |
| 2019-01-11 | New | $5,000,000 | $5,000,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Graham Anderson | Executive, Promoter |
| Mark Glasgold | Director |
| Christine Li | Director |
| Robert Chad Mc Clennan | Executive, Promoter |
| Robert Chad Mcclennan | Executive, Promoter |
| Gregory Moran | Director |
| William E. Peterson | Director |
| Christine Li Shuling | Executive, Promoter |
| John Walker | Executive, Promoter |